Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhiguo Wang has a total of 237 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Photoenzymatic stereodivergent hydrophosphinylation enabled by nicotinamide-dependent imine reductases

    by Kaihao Mou, Zehua Tian, Weihua Xu, Xiuwen Kang, Yuyang Ma, Peixuan Zhuang, Zhenyu Lu, Jingxin Zhang, Yue Guo, Leyan Xu, et al.


  • A biocatalytic platform for the stereoselective synthesis of diverse atropisomeric compounds using engineered metalloenzymes

    by Xiaochen Cai, Dong Cui, Yuchen Chu, Yanan Rui, Xinyu Duan, Yongzhen Peng, Zhiguo Wang, Jian Xu

    Atropisomeric compounds are widely distributed in natural products and pharmaceuticals and serve as key scaffolds in asymmetric catalysis. Despite their remarkable structural diversity, current synthetic efforts have primarily focused on C–C biaryl atropisomers, while the synthesis of other classes of atropisomeric compounds has been much less explored. Biocatalysis offers precise control over the stereoselectivity of reactions, however, its application in the synthesis of atropisomeric compounds remains at an early stage. In this work, we report a versatile biocatalytic platform that integrates metalloenzyme-catalyzed reduction reactions to access a broad array of structurally diverse atropisomeric compounds, including C–N atropisomers, diaryl ethers, and styrene derivatives, with high yields and excellent enantioselectivities. Molecular dynamics simulations provided mechanistic insights into the origin of the high stereoselectivity, and this study expands the repertoire of metalloenzyme-catalyzed, new-to-nature transformations for the synthesis of valuable molecules.

  • Open Access

    Engineered suppressor tRNAs enable precise translational control of genetic circuits in E. coli

    by Xiaotong Wang, Jianping Xu, Yipeng Wang, Qingsheng Qi, Zhiguo Wang, Qian Wang

    Precise and orthogonal regulation of genetic circuits is a central challenge in synthetic biology, particularly at the translational level where tools remain scarce. Here, we address this by engineering suppressor transfer RNAs (sup-tRNAs) charged with canonical amino acids to enable programmable nonsense mutation readthrough in Escherichia coli. Screening of 20 variants revealed a clear sup-tRNA design rule: readthrough efficiency is dictated by the similarity of the native tRNA anticodon to amber codon (CUA), as it preserves native aaRS interactions. We then demonstrate the power of this tool for advanced genetic circuit engineering. First, in a LacI-based biosensor, sup-tRNA regulation reduced background leakage by >77% and increased the induction dynamic range by 4.3-fold (from 6.67 to 28.68). Second, by dynamically balancing glycolytic flux through targeted pykA and pykF regulation, we increased the titer of N-acetylneuraminic acid by 66% (from 5.33 to 8.82 g/l) without compromising cell growth. Our work establishes engineered cAA-charged sup-tRNAs as a versatile, efficient, and cost-effective platform for precision translational control within genetic circuits, opening new avenues for biosensor optimization and metabolic engineering.


  • Open Access

    Stereoselective cyano translocation reaction enabled by photoenzymatic catalysis

    by Xinyu Duan, Jie Xu, Rulin Bai, Chenlu Jin, Yuchen Chu, Guojing Wu, Liangliang Pan, Chunlei Yang, Zhiguo Wang, Jian Xu

    Functional-group translocation constitutes a powerful strategy in organic synthesis, allowing precise modification of molecular architectures and functional group positions. Nevertheless, methodologies capable of delivering precise stereocontrol during such migrations remain exceedingly scarce. Herein, we present a photoenzymatic strategy for cyano translocation that achieves precise stereocontrol. The use of stereo-complementary enzymes grants access to both enantiomers, while mechanistic studies and molecular dynamics simulations delineate the origin of stereoselectivity. This work expands the paradigm of transformations that can be rendered asymmetric by photoenzymatic catalysis and provides a new strategy to tackle persistent challenges in organic synthesis.


  • Open Access

    Cofactor-independent photo-enzymatic reductions with water mediated by reductive graphene quantum dots

    by Anming Wang, Xiaoyu Li, Li Qiao, Xiaoting Pan, Yongjian Jiang, Zhiguo Wang, Wei Ye, Peng Gao, Roger A. Sheldon

    Enzymatic reductions catalyzed by reductases generally depend on reduced nicotinamide cofactors as a hydride source. However, for industrial viability, it is more cost-effective to use water as the hydrogen source, bypassing the requirement for the cofactor. Here we report a hybrid photo-biocatalyst system based on infrared (IR) light and responsive reductive graphene quantum dots (rGQDs), for performing the direct transfer of hydrogen from water to prochiral substrates. The photo-biocatalyst, assembled from rGQDs and cross-linked aldo-keto reductase (AKR), mediates the synthesis of the pharmaceutical intermediate, (R)−1-[3,5-bis(trifluoromethyl)-phenyl] ethanol ((R)−3,5-BTPE), in 82% yield and >99.99% ee under IR illumination. Our photo-enzymatic systems can also be effectively used to drive the enzymatic reduction of imines and alkenes. Since the hybrid photo-biocatalysts are insoluble, they can be readily recovered and recycled. This work opens new avenues to create artificial photo-biocatalyst systems, enabling the facile coupling of renewable solar energy and sustainable chemical production.


  • Open Access

    Photoenzymatic stereodivergent hydrophosphinylation to access diverse P-chirogenic and P-/C-bichirogenic phosphorus compounds

    by Kaihao Mou, Zehua Tian, Weihua Xu, Xiuwen Kang, Zhiguo Wang, Bei Ding, Qi Wu

    Phosphorus-radical chemistry faces a major challenge in achieving stereochemical control over radical intermediates, a key requirement for accessing diverse P-chirogenic phosphorus compounds that are widely applied in pharmaceuticals, agrochemicals, and materials1–4. Enzymes capable of catalyzing chiral carbon-phosphorus (C-P) bond formation remain scarce5, limiting the biosynthetic development of chiral organophosphorus compounds. Recent advances in non-natural photoenzymatic catalysis expanded the radical reactivity repertoire of biocatalysis, yet P-centered radical transformations remain unexplored6,7. Consequently, the asymmetric synthesis of diverse P- chirogenic or P-/C-bichirogenic phosphorus compounds through highly stereocontrolled phosphorus-radical transformations remains an unmet challenge in both chemical and enzymatic catalysis. In this study, a nicotinamide-dependent imine reductase was repurposed into an asymmetric hydrophosphinylation enzyme (AHP), enabling single-electron oxidation of secondary phosphine oxides to generate P-centered radicals and facilitate subsequent C-P coupling in a redox-neutral, stereoselective fashion. Several series of tertiary phosphine oxide products bearing C-, P-, or P-/C-bistereocenters were prepared using stereodivergent mutants obtained through a focused site-directed evolution strategy. Mechanistic studies reveal a previously unobserved pathway involving single-electron oxidation of the substrate, initiated by photoexcited NADP+. This study advanced enzymatic strategies for chiral P-C coupling and addressed longstanding challenges in achieving stereocontrol over P- and P-/C-bistereocentered radical intermediates in radical chemistry.


  • Open Access

    UFMylation: A supervisor of the HIF1α pathway and a potential therapeutic target for anti-PD-1 combination therapy in hypoxic tumors

    by Yongkang Zou, Zhaoxiang Wang, Qiang Jiang, Xia Kong, Xiaohe Ma, Zhengyan Liang, Zhiguo Wang, Beiying Chen, Jiao Yuan, Jiayue Wen, et al.

    Activation of hypoxia signaling has been identified as an innate resistance signature against anti-PD-1 therapy, suggesting its potential as a target for combination treatments. Here, we demonstrate that UFMylation modification of HIF1α stabilizes the protein by antagonizing its ubiquitination and proteasomal degradation under hypoxic conditions. Mechanistically, depletion of UFL1 or defective UFMylation increases HIF1α binding to p53, promoting its degradation. Depletion of UFL1 or UBA5 , or defective UFMylation of HIF1α, destabilizes HIF1α, significantly inhibiting tumor growth and development in vitro and in xenograft mouse models. Defective UFMylation of HIF1α enhances the response to anti-PD-1 therapy in xenograft models. Clinically, UBA5 expression is upregulated in breast cancer tissues, and a selective UBA5 inhibitor reduces UFMylation activity and HIF1α protein levels, thereby enhancing anti-PD-1 combination therapy in mouse tumor models. Our findings highlight UFMylation as a critical posttranslational modification for the HIF1α pathway and a promising therapeutic target in hypoxic tumors.


  • Open Access

    Neurodegenerative disorders reversed by ATP13A2 flipping sphingomyelin across lysosome

    by Junping Liu, Jianfeng Li, Yanhua Lu, Ying Tang, Zhiguo Wang, Yuhang Shen, Lihui Wang, Haibang Hao, Gang Chen, Mengxin Zhang

    Neurodegenerative disorders involve ATP13A2 gene mutations in Parkinson’s disease (PD), Kufor-Rakeb syndrome (KRS), spastic paraplegia (SPG), neuronal ceroid lipofuscinosis (NCL), and amyotrophic lateral sclerosis (ALS). Here, we report that the P-type ATPase transporter ATP13A2 (PARK9) transports sphingomyelin (SM) across the lysosomal membrane for recycling to the cell membrane, by an ATP hydrolysis-dependent transbilayer flip-flop mechanism. ATP13A2 inactivation induces SM lysosomal storage disorder (smLSD). Sustained smLSD triggers glycosphingolipid catabolism with neuronal SM insufficiency, ceramide spillover, and autofluorescent ceroid lipofuscins in mice, recapitulating clinical ATP13A2 mutation-caused impulsive behaviour and movement disorders. Drug screening identifies that FTY720 (fingolimod) inhibits sphingomyelinase cleaving SM to ceramide, reversing ATP13A2 knockout-induced SM shortfall, ceramide accumulation, monoaminergic neurotransmission defect and motor paralysis. These findings demonstrate that ATP13A2 is a SM flippase, smLSD underpins neurodegeneration, and inhibiting sphingomyelin/ceramide imbalance attenuates neurodegenerative disorders with ATP13A2 mutation, providing a framework for prophylactic/therapeutic interventions in PD-ICD, KRS, SPG, NCL, and ALS.


  • Sequence Similarity Network Guided Discovery of a Dehydrogenase for Asymmetric Carbonyl Dehydrogenation

    by Yujing Hu, Jie Chen, Shaofang Qi, Hui Wang, Zhaoxuan Zhu, Yongzhen Peng, Wenjing Wang, Guixiang Huang, Zheng Fang, Yuxuan Ye, et al.

    Carbonyl dehydrogenation is one of the most valuable transformations in modern synthetic chemistry. As compared to traditional chemical synthesis methods, enzymatic dehydrogenation offers a greener and more selective alternative. However, except for a few rare natural dehydrogenases for desaturation, current enzymatic methods predominantly rely on enzyme promiscuity, which often suffers from lower efficiency and limited reaction controllability. Herein, we employed sequence similarity networks to mine natural dehydrogenases from a vast array of sequences with potential dehydrogenation activity. This approach led to the discovery of an uncharacterized FAD‐dependent enzyme capable of efficiently performing the desymmetrizing desaturation of cyclohexanones, thereby generating diverse cyclohexenones bearing remote γ‐quaternary stereocenters. The current method has enhanced the turnover frequency (TOF) by approximately 178‐fold as compared to the best existing biocatalytic strategies and displayed almost no overoxidation reactions. Through a combination of experimental assays and computational studies, we elucidated that this enzyme enhances its dehydrogenation capability through an unconventional proton relay system, absent in previously reported enzyme promiscuity systems. Additionally, this streamlined enzymatic process demonstrated scalability to gram‐scale synthesis with maintained efficiency and selectivity, offering robust and sustainable alternatives for the synthesis of chiral cyclohexenones with high optical purity.